Novel cancer treatment resistance mechanism uncovered
2 August 2018
BRCA1 deficiencies cause breast and ovarian cancer, rendering tumours hypersensitive to PARP inhibitors. Patient treatment can become ineffective due to emerging resistance mechanisms. Ross Chapman’s team at the Welcome Centre has uncovered a protein complex termed Shieldin that acts with 53BP1 to limit end resection at DNA double-strand breaks, which confers resistance to cancer treatment.